rDNA insulin glargine U300 – a critical appraisal

References

• Bolli G Owens D Insulin glargine Lancet 2000 356 9228 443 445 10981882
   PubMed Web of Science ®Google Scholar
• Riddle MC Rosenstock J Gerich J The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003 26 11 3080 3086 14578243
   PubMed Web of Science ®Google Scholar
• Gerstein HC Bosch J Dagenais GR Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012 367 4 319 328 22686416
   PubMed Web of Science ®Google Scholar
• Davies M Lavalle-González F Storms F Gomis R Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the ATLANTUS trial Diabetes Obes Metab 2008 10 5 387 399 18355327
   PubMed Web of Science ®Google Scholar
• Sanofi: Confronting Lantus patent expiry with more efficient successor Toujeo 2014 Available from: http://seekingalpha.com/article/2395325-sanofi-confronting-lantus-patent-expiry-with-more-efficient-successor-toujeo. Updated August 7, 2014 Accessed August 10, 2016
   Google Scholar
• U.S. food and drug administration FDA approves basaglar, the first “follow-on” insulin glargine product to treat diabetes 2015 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm. Updated December 16, 2015 Accessed August 10, 2016
   Google Scholar
• U.S. FDA news release FDA approves two new drug treatments for diabetes mellitus 2015 Available from: http://www.fda.gov/News-Events/Newsroom/PressAnnouncements/ucm464321.htm. Updated September 25, 2015 Accessed August 10, 2016
   Google Scholar
• Owens DR Matfin G Monnier L Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res 2014 30 2 104 119
   Web of Science ®Google Scholar
• Monami M Marchionni N Mannucci E Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis Diabetes Obes Metab 2009 11 372 378 19267715
   PubMed Web of Science ®Google Scholar
• Monami M Marchionni N Mannucci E Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis Diabetes Res Clin Pract 2008 81 2 184 189 18495286
   PubMed Web of Science ®Google Scholar
• Abali S Turan S Atay Z Güran T Haliloglu B Bereket A Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus Pediatr Diabetes 2015 16 5 361 366 25039448
   PubMed Web of Science ®Google Scholar
• Bryant GA McDanel DL Horner KE Farris KB Newkirk EN Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir Pharmacotherapy 2013 33 1 56 62 23307546
   PubMed Web of Science ®Google Scholar
• Swinnen SG Simon AC Holleman F Hoekstra JB Devries JH Insulin detemir versus insulin glargine for type 2 diabetes mellitus Cochrane Database Syst Rev 2011 6 7 CD006383
   Google Scholar
• Wallace JP Wallace JL McFarland MS Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? Ann Pharmacother 2014 48 3 361 368 24396092
   PubMed Web of Science ®Google Scholar
• Ashwell SG Gebbie J Home PD Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart Diabet Med 2006 23 879 886 16911626
   PubMed Web of Science ®Google Scholar
• Umesh D Castro E Insulin U100, 200, 300, or 500? Br J Diabetes 2016 16 10 15
   Google Scholar
• Jonassen I Havelund S Hoeg-Jensen T Steensgaard DB Wahlund PO Ribel U Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin Pharm Res 2012 29 8 2104 2114 22485010
   PubMed Web of Science ®Google Scholar
• Heise T Nosek L Bøttcher S Hastrup H Haahr H Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes Diabetes Obes Metab 2012 14 10 944 950 22726241
   PubMed Web of Science ®Google Scholar
• Heise T Hermanski L Nosek L Feldman A Rasmussen S Haahr H Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes Diabetes Obes Metab 2012 14 9 859 864 22594461
   PubMed Web of Science ®Google Scholar
• European Medicine Agency Abasaglar: Summary of Product Characteristics 2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/. Updated September 9, 2014 Accessed August 10, 2016
   Google Scholar
• Becker RH Dahmen R Bergmann K Lehmann A Jax T Heise T New insulin glargine 300 units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units · mL-1 Diabetes Care 2015 38 4 637 643 25150159
   PubMed Web of Science ®Google Scholar
• Jax T Heise T Dahmen R New insulin glargine formulation has a flat and prolonged steady state profile in subjects with type 1 diabetes [abstract] Diabetologia 2013 56 Suppl 1 A1029
   Google Scholar
• Riddle MC Lessons from peglispro: IMAGINE how to improve drug development and affordability Diabetes Care 2016 39 4 499 501 27208365
   PubMed Web of Science ®Google Scholar
• Terauchi Y Koyama M Cheng X New insulin glargine 300 U/mL versus glargine 100 U/mL in japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2) Diabetes Obes Metab 2016 18 4 366 374 26662838
   PubMed Web of Science ®Google Scholar
• Toujeo® (insulin glargine 300 units/mL) [prescribing information] Bridgewater, NJ Sanofi-Aventis U.S. LLC 2015
   Google Scholar
• European Medicines Agency Toujeo (insulin glargine U300): Summary of product characteristics 2016 Available from: http://www.ema.europa.eu. Updated February 2015 Accessed July 29, 2016
   Google Scholar
• Wang F Carabino JM Vergara CM Insulin glargine: a systematic review of a long-acting insulin analogue Clin Ther 2003 25 6 1541 1577 12860485
   PubMed Web of Science ®Google Scholar
• Bolli GB DeVries JH New long-acting insulin analogs: from clamp studies to clinical practice Diabetes Care 2015 38 4 541 543 25805863
   PubMed Web of Science ®Google Scholar
• Steinstraesser A Schmidt R Bergmann K Dahmen R Becker RH Investigational new insulin glargine 300 U/mL has the same metabolism as insulin glargine 100 U/mL Diabetes Obes Metab 2014 16 9 873 876 24571126
   PubMed Web of Science ®Google Scholar
• Riddle MC Bolli GB Ziemen M Muehlen-Bartmer I Bizet F Home PD New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1) Diabetes Care 2014 37 10 2755 2762 25078900
   PubMed Web of Science ®Google Scholar
• Shiramoto M Eto T Irie S Single-dose new insulin glargine 300 U/mL provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes Diabetes Obes Metab 2015 17 3 254 260 25425297
   PubMed Web of Science ®Google Scholar
• Tillner JA Bergmann K Teichert L Dahmen R Heise T Becker RH Euglycaemic single dose clamp profile of new insulin glargine formulation in subjects with type 1 diabetes is flat and prolonged [abstract no. 1033] Diabetologia 2013 56 Suppl 1 S415
   Google Scholar
• Becker RH Nowotny I Teichert L Bergmann K Kapitza C Low within- and between-day variability in exposure to new insulin glargine 300 U/mL Diabetes Obes Metab 2015 17 3 261 267 25425394
   PubMed Web of Science ®Google Scholar
• Jinnouchi H Koyama M Amano A Continuous glucose monitoring during Basal–Bolus therapy using insulin glargine 300 U mL-1 and glargine 100 U mL-1 in Japanese people with type 1 diabetes mellitus: a crossover pilot study Diabetes Ther 2015 6 2 143 152 26055218
   PubMed Web of Science ®Google Scholar
• Monnier L Owens DR Bolli GB The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation Diabetes Metab 2016 42 2 77 79 26688145
   PubMed Web of Science ®Google Scholar
• Lucidi P Porcellati F Rossetti P Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes Diabetes Care 2012 35 12 2647 2649 23086139
   PubMed Web of Science ®Google Scholar
• Yki-Jaervinen H Bergenstal R Ziemen M New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) Diabetes Care 2014 37 3235 3243 25193531
   PubMed Web of Science ®Google Scholar
• Bolli GB Riddle MC Bergenstal RM New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) Diabetes Obes Metab 2015 17 4 386 394 25641260
   PubMed Web of Science ®Google Scholar
• Home PD Bergenstal RM Bolli GB New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4) Diabetes Care 2015 38 12 2217 2225 26084341
   PubMed Web of Science ®Google Scholar
• Matsuhisa M Koyama M Cheng X New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypo-glycaemia in a randomized controlled trial (EDITION JP 1) Diabetes Obes Metab EDITION JP 1 2016 18 4 375 383 26662964
   PubMed Web of Science ®Google Scholar
• Riddle MC Yki-Järvinen H Bolli GB One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/mL compared with 100 U/mL in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension Diabetes Obes Metab 2015 17 9 835 842 25846721
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H Bergenstal RM Bolli GB Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus insulin glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension Diabetes Obes Metab 2015 17 12 1142 1149 26172084
   PubMed Web of Science ®Google Scholar
• Terauchi Y Koyama M Cheng X Sumi M Hirose T Sustained glycaemic control and less hypoglycaemia over 1y with new insulin glargine 300 U/mL vs glargine 100 U/mL in japanese type 2 diabetes mellitus people on basal insulin + OAD(s) (EDITION JP 2) [abstract no. 94-LB] Diabetes 2014 63 Suppl 1A LB24
   Google Scholar
• Matsuhisa M Koyama M Cheng X Sumi M Hirose T Sustained glycemic control and less nocturnal hypoglycemia with new insulin glargine 300 U/mL compared with glargine 100 U/mL over 12 months in japanese people with T1DM (EDITION JP 1) [abstract no. 987-P] Diabetes 2015 64 Suppl 1 A250
   Google Scholar
• Ritzel R Roussel R Bolli GB Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes Diabetes Obes Metab 2015 17 9 859 867 25929311
   PubMed Web of Science ®Google Scholar
• Ritzel R Roussel R Giaccari A Glycemic control and hypoglycemia with insulin glargine 300 U/mL (gla-300) vs. gargline 100 U/mL (gla-100) in type 2 diabetes (T2DM) in a patient-level meta-analysis of 1-yr phase 3a EDITION studies [abstract no. 1030-P] Diabetes 2015 64 Suppl 1 A264
   Google Scholar
• Freemantle N Chou E Frois C Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis BMJ Open 2016 6 2 e009421 10.1136/bmjopen-2015-009421
   Web of Science ®Google Scholar
• Twigg SM Escalada J Grisoni M Age, BMI, and diabetes duration: effect on glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes (T2DM) [abstract no. 1017-P] Diabetes 2015 64 Suppl 1 A260
   Google Scholar
• Yale J Aroda V Charbonnel B Older people with type 2 diabetes: glycemic control and hypoglycemia risk with new insulin glargine 300 U/mL [abstract no. 991-P] Diabetes 2015 64 Suppl 1 A252
   Google Scholar
• Buzzetti R Pettus JH Brito-Sanfiel M New insulin glargine 300 U/mL (gla-300) in combination with dipeptidyl peptidase IV inhibitors in T2DM (EDITION 2 and 3): glycemic control and hypoglycemia [abstract no. 95-LB] Diabetes 2015 64 Suppl A1 LB24
   Google Scholar
• Escalada J Halimi S Senior PA Glycemic control and hypoglycemia benefits with insulin glargine 300 U/mL (gla-300) extend to people with type 2 diabetes (T2DM) and mild-to-moderate renal impairment [abstract no. 69-OR] Diabetes 2016 65 Suppl 1 A18
   Google Scholar
• American diabetes association workgroup on hypoglycemia Defining and reporting hypoglycemia in diabetes: a report from the american diabetes association workgroup on hypoglycemia Diabetes care 2015 28 1245 1249
   Google Scholar
• Reid T Odugbesan O Gill J Nikonova E Chao J Bailey TS Reduced hypoglycemia and comparable efficacy with insulin glargine 300 U/mL (gla-300) vs. insulin glargine 100 U/mL (gla-100) in subjects with T2D achieving different levels of prebreakfast SMPG [abstract no. 95-LB] Diabetes 2016 65 Suppl 1 A LB25 26
   Google Scholar
• Roussel R D’Emden MC Fisher M Switching from twice-daily basal insulin to once-daily new insulin glargine 300 U/mL (gla-300): an analysis in people with T2DM (EDITION 1 and 2) [abstract no. 1021-P] Diabetes 2015 64 Suppl 1 A261
   Google Scholar
• Riddle MC Home PD Avogaro A A clinically-defined nocturnal window for analysis of hypoglycemia with new insulin glargine 300 U/mL in type 2 diabetes (T2DM) [abstract no. 1027-P] Diabetes 2015 64 Suppl 1 A263
   Google Scholar
• Bolli GB Wysham CH Fisher M Wider windows for evaluating nocturnal hypoglycemia capture more events and confirm lower nocturnal hypoglycemia risk with insulin glargine 300 U/mL (gla-300) vs. 100 U/mL (gla-100) in T2DM [abstract no. 91-LB] Diabetes 2016 65 Suppl 1 A LB24
   Google Scholar
• Bonadonna RC Yale J Brulle-Wohlhueter C Boelle-Le Corfec E Choudhary P Bailey TS Hypoglycemia as a function of HbA1c in type 2 diabetes (T2DM): insulin glargine 300 U/mL in a patient-level meta-analysis of EDITION 1,2, and 3 [abstract no. 928-P] Diabetes 2016 65 Suppl 1 A239
   Google Scholar
• Rosenstock J Ritzel RA Chevalier S Balkau B Roussel R Clinical perspectives from the BEGIN and EDITION longer-acting insulin programs: trial-level meta-analyses outcomes with either degludec (IDeg) or glargine 300 U/mL (gla-300) vs. glargine 100 U/mL (gla-100) in T2DM [abstract no. 962-P] Diabetes 2016 65 Suppl 1 A249
   Google Scholar
• Stella P Aroda V Charbonnel B Older people with type 2 diabetes: glycaemic control and hypoglycaemia risk with new insulin glargine 300 U/mL (gla-300) Diabetologia 2015 58 Suppl 1 S473
   Google Scholar
• Riddle MC Bolli GB Home PD Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 u/mL in people with type 2 diabetes Diabetes Technol Ther 2016 18 4 251 257
   Web of Science ®Google Scholar
• Klonoff D Nayberg I Thonius M Accuracy and injection force of the gla-300 injection device compared with other commercialized disposable insulin pens J Diabetes Sci Technol 2015 10 1 125 130 26311720
   PubMedGoogle Scholar
• Pohlmeier H Klonoff DC Berard L Ease of use of the new insulin glargine 300 U/mL solostar pen injector in insulin-naive people with type 2 diabetes [abstract no. 1052-P] Diabetes 2015 64 Suppl 1 A269 A270
   Google Scholar
• Klonoff D Nayberg I Erbstein F Cali A Brulle-Wohlhueter C Haak T Usability of the gla-300 injection device compared with three other commercialized disposable insulin pens: results of an interview-based survey J Diabetes Sci Technol 2015 9 4 936 938 26002837
   PubMedGoogle Scholar
• Ye F Agarwal R Kaur A Real-world assessment of patient characteristics and clinical outcomes of early users of the new insulin glargine 300 U/mL [abstract no. 943-P] Diabetes 2016 65 Suppl 1 A243
   Google Scholar
• Meneghini L Lingvay I Chao J Stuhr A Kazemi M Dalal M Efficacy and safety of new insulin glargine 300 units/mL in insulin-naïve patients with type 2 diabetes mellitus (EDITION 3) using selected HEDIS measures [abstract no. THR-660] Presented at: The Endocrine Society’s 97th Annual Meeting & Expo March 5; 2015 San Diego, CA
   Google Scholar
• Hood RC Arakaki RF Wysham CH Li Y Settles JA Jackson JA Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized titration-to-target clinical trial Endocr Pract 2015 21 7 782 793 25813411
   PubMed Web of Science ®Google Scholar
• Mari A Rosenstock J Ma YL Jackson JA Optimized human regular U-500 insulin treatment improves beta-cell function in severely insulin-resistant patients with long-standing type 2 diabetes and high insulin requirements Endocr Pract 2015 21 12 1344 1352 26307903
   PubMed Web of Science ®Google Scholar